VISEN PHARMA-B (02561) Surges Over 9% Intraday, Core Product Lonapegsomatropin Expected to Gain Approval Soon

Stock News

Jan 23

VISEN PHARMA-B (02561) saw its shares jump more than 9% during the trading session. As of the time of writing, the stock was up 7.13%, trading at HK$37.24. According to the Insight database, the company's core product, Lonapegsomatropin, exited the supplementary data request stage on January 12, 2026, indicating that regulatory approval is anticipated imminently. Public information shows that Lonapegsomatropin is a long-acting growth hormone prodrug introduced by VISEN PHARMA-B from Ascendis Pharma. It is developed based on the TransCon temporary linkage technology for the treatment of pediatric growth hormone deficiency (GHD), administered via once-weekly subcutaneous injection, and releases unmodified natural human growth hormone, having already received approval in Europe and the United States. The domestic growth hormone market is currently dominated by daily formulations. The introduction of a weekly formulation is expected to significantly enhance patient compliance, potentially reshape the competitive landscape upon market entry, and address a substantial unmet clinical need.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1191373163"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1191373163\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1191373163?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-23 11:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191373163","market":"hk","top_or_hot":-1,"title":"VISEN PHARMA-B (02561) Surges Over 9% Intraday, Core Product Lonapegsomatropin Expected to Gain Approval Soon","media":"Stock News","content":"<p>VISEN PHARMA-B (02561) saw its shares jump more than 9% during the trading session. As of the time of writing, the stock was up 7.13%, trading at HK$37.24.\nAccording to the Insight database, the company's core product, Lonapegsomatropin, exited the supplementary data request stage on January 12, 2026, indicating that regulatory approval is anticipated imminently.\nPublic information shows that Lonapegsomatropin is a long-acting growth hormone prodrug introduced by VISEN PHARMA-B from Ascendis Pharma. It is developed based on the TransCon temporary linkage technology for the treatment of pediatric growth hormone deficiency (GHD), administered via once-weekly subcutaneous injection, and releases unmodified natural human growth hormone, having already received approval in Europe and the United States.\nThe domestic growth hormone market is currently dominated by daily formulations. The introduction of a weekly formulation is expected to significantly enhance patient compliance, potentially reshape the competitive landscape upon market entry, and address a substantial unmet clinical need.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VISEN PHARMA-B (02561) Surges Over 9% Intraday, Core Product Lonapegsomatropin Expected to Gain Approval Soon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVISEN PHARMA-B (02561) Surges Over 9% Intraday, Core Product Lonapegsomatropin Expected to Gain Approval Soon\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-23 11:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>VISEN PHARMA-B (02561) saw its shares jump more than 9% during the trading session. As of the time of writing, the stock was up 7.13%, trading at HK$37.24.\nAccording to the Insight database, the company's core product, Lonapegsomatropin, exited the supplementary data request stage on January 12, 2026, indicating that regulatory approval is anticipated imminently.\nPublic information shows that Lonapegsomatropin is a long-acting growth hormone prodrug introduced by VISEN PHARMA-B from Ascendis Pharma. It is developed based on the TransCon temporary linkage technology for the treatment of pediatric growth hormone deficiency (GHD), administered via once-weekly subcutaneous injection, and releases unmodified natural human growth hormone, having already received approval in Europe and the United States.\nThe domestic growth hormone market is currently dominated by daily formulations. The introduction of a weekly formulation is expected to significantly enhance patient compliance, potentially reshape the competitive landscape upon market entry, and address a substantial unmet clinical need.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1610","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"","article_id":"1191373163","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191373163","pubTimestamp":1769140696,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"VISEN PHARMA-B (02561) saw its shares jump more than 9% during the trading session. As of the time of writing, the stock was up 7.13%, trading at HK$37.24. According to the Insight database, the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1610":"ETF&股票定投概念","BK1161":"生物科技","02561":"维昇药业-B","02800":"盈富基金"},"translate_title":"维森制药-B(02561)盘中大涨超9%核心产品Lonapegsomatropin有望很快获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02800":1,"02561":1},"content_text":"VISEN PHARMA-B (02561) saw its shares jump more than 9% during the trading session. As of the time of writing, the stock was up 7.13%, trading at HK$37.24.\nAccording to the Insight database, the company's core product, Lonapegsomatropin, exited the supplementary data request stage on January 12, 2026, indicating that regulatory approval is anticipated imminently.\nPublic information shows that Lonapegsomatropin is a long-acting growth hormone prodrug introduced by VISEN PHARMA-B from Ascendis Pharma. It is developed based on the TransCon temporary linkage technology for the treatment of pediatric growth hormone deficiency (GHD), administered via once-weekly subcutaneous injection, and releases unmodified natural human growth hormone, having already received approval in Europe and the United States.\nThe domestic growth hormone market is currently dominated by daily formulations. The introduction of a weekly formulation is expected to significantly enhance patient compliance, potentially reshape the competitive landscape upon market entry, and address a substantial unmet clinical need.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}